Ligand Pharmaceuticals

LGND | NASDAQ

Price Alert Chart Builder DCF Calculator

$290.07

+$6.58 (+2.32%)

At close: Sep 21, 2026, 4:00 PM ET

$289.21

-$0.86 (-0.30%)

Pre-market: Sep 22, 2026, 8:49 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Income Statement Balance Sheet Cashflow Statement Ratios

Annual Quarterly TTM

Fiscal Year Period Ending	FY 2025 Dec 30, 2025	FY 2024 Dec 30, 2024	FY 2023 Dec 30, 2023	FY 2022 Dec 30, 2022	FY 2021 Dec 30, 2021	FY 2020 Dec 30, 2020
Revenue	268.09M	167.13M	131.31M	196.25M	241.54M	163.56M
Cost of Revenue	6.59M	11.07M	35.05M	52.83M	62.18M	30.42M
Gross Profit	261.5M	156.06M	96.27M	143.42M	179.37M	133.14M
Operating Income	47.2M	-22.61M	11.94M	3.04M	103.85M	37.5M
Interest Income	13.66M	8.06M	7.71M	2.05M	886K	8.08M
Pretax Income	158.96M	2.52M	63.66M	36.01M	72.21M	1.29M
Net Income	124.45M	-4.03M	52.15M	-33.36M	57.14M	-2.99M
Selling & General & Admin	92.45M	78.65M	52.79M	70.06M	46.79M	60.01M
Research & Development	81.18M	21.43M	24.54M	36.08M	32.11M	40.5M
Other Expenses	40.67M	78.59M	7M	34.24M	-3.38M	-4.87M
Operating Expenses	214.3M	178.67M	84.32M	140.38M	75.52M	95.64M
Interest Expense	4.72M	3.04M	656K	1.8M	19.62M	27.42M
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	220.89M	189.74M	119.37M	193.21M	137.69M	126.06M
Income Tax Expense	34.51M	6.55M	9.84M	41.23M	-4.15M	-5.31M
Shares Outstanding (Basic)	19.34M	18.29M	17.3M	16.87M	16.63M	16.19M
Shares Outstanding (Diluted)	20.29M	18.29M	17.76M	16.87M	17.25M	16.19M
EPS (Basic)	6.44	-0.22	3.02	-1.98	3.46	-0.18
EPS (Diluted)	6.13	-0.22	2.94	-1.98	3.34	-0.18
EBITDA	192.74M	40.79M	100.84M	81.2M	142.77M	56.67M
EBIT	158.96M	5.56M	64.32M	37.81M	91.82M	28.71M
Depreciation & Amortization	33.78M	35.24M	36.52M	43.39M	50.95M	27.97M